title: Anti-inflammatory activity of lanoconazole, a topical antifungal agent.
abstract: Topical antifungal agents which have anti-inflammatory effects have the potential to provide additional clinical benefits. Therefore, an anti-inflammatory activity of lanoconazole (LCZ), a topical antifungal agent, was investigated against in vitro and in vivo models of inflammation. The release of interleukin-8 (IL-8) from human epidermal keratinocytes stimulated by the addition of 100 μg ml(-1) β-glucan of Saccharomyces cerevisiae was significantly inhibited by LCZ at the concentration of 10(-5) mol l(-1). The release of interferon-γ and IL-2 from human peripheral blood mononuclear cells stimulated by the addition of 30 and 100 μg ml(-1) phytohemagglutinin was significantly inhibited by LCZ at the concentrations of 10(-7) and 10(-6) mol l(-1), respectively. The increase in the ear thickness induced by topical application of 0.01% 12-O-tetradecanoyl phorbol-13-acetate and 1% 2,4,6-trinitrochlorobenzene (TNCB) after sensitisation with 3% TNCB were established as the mouse models of irritant and contact dermatitis, respectively. Application of 1% and 3% LCZ showed a significant anti-inflammatory activity against both the irritant and contact dermatitis models. These findings suggest that LCZ possesses an anti-inflammatory activity, which may be partially helpful in the treatment of dermatomycoses.
authors: Research Laboratories, Kyoto R&D Center, Maruho Co., Ltd., Kyoto, Japan.
authors: Hideya
authors: H
authors: Uratsuji
authors: Aki
authors: A
authors: Nakamura
authors: Yoshihito
authors: Y
authors: Yamada
authors: Kei
authors: K
authors: Hashimoto
authors: Tatsumi
authors: T
authors: Matsumoto
authors: Fumiaki
authors: F
authors: Ikeda
authors: Ritsuko
authors: R
authors: Ishii
mesh_terms: D000279:Administration, Cutaneous; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D002478:Cells, Cultured; D003877:Dermatitis, Contact / Q000188:drug therapy; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D007371:Interferon-gamma / Q000378:metabolism; D007376:Interleukin-2 / Q000378:metabolism; D016209:Interleukin-8 / Q000276:immunology / Q000378:metabolism*; D015603:Keratinocytes / Q000187:drug effects* / Q000276:immunology; D007963:Leukocytes, Mononuclear / Q000187:drug effects* / Q000276:immunology; D051379:Mice; D010835:Phytohemagglutinins / Q000276:immunology; D012441:Saccharomyces cerevisiae / Q000737:chemistry; D047071:beta-Glucans / Q000276:immunology
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D007093:Imidazoles; D007376:Interleukin-2; D016209:Interleukin-8; D010835:Phytohemagglutinins; D047071:beta-Glucans; C072774:latoconazole; D007371:Interferon-gamma
keywords: Lanoconazole; anti-inflammatory activity; contact dermatitis; dermatomycoses; irritant dermatitis; topical antifungal agent